Temozolomide — the oral alkylating agent that has become a cornerstone in the treatment of glioblastoma multiforme and other aggressive brain tumors — commands a robust and growing global pharmaceutical market. With the global temozolomide market estimated at USD 1.44 billion in 2026 and projected to reach USD 2.44 billion by 2033 at a CAGR of 7.8%, understanding who buys temozolomide, where they are located, and how the supply chain operates is essential for manufacturers, distributors, and procurement professionals alike. This comprehensive guide delivers a verified temozolomide global buyers list based on Indian Customs (DGFT) data, covering 250+ active importers across 90+ countries, with detailed market share analysis, top buyer…